[7] All potential female patients are screened and counseled on this point, and effective contraception is recommended for those undergoing NAD+ therapy if applicable
Sports Eligibility Risk : Athletes face eligibility concerns because WADA prohibits unapproved substances, and BPC-157 is commonly discussed within that restricted category
If someone has a diagnosed deficiency, especially due to absorption issues, their provider might start them on weekly injections
This is normal and the sensation should subside shortly after the injection is completed
How it helps & what to expect Your questions, answered Education only not medical advice
Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
